Tuesday, November 01, 2005

NNVC

NNVC has begun preclinical studies on one if it's products, Flucide-I, an anti-viral. This was expected, nonetheless, is big news. I added to my NNVC position yesterday at 55 cents.



NanoViricides Has Begun Preclinical Studies For Their First Anti-Viral Drug Targeted Against Bird Flu

Monday October 31, 8:00 am ET

Studies Are Being Conducted at the Beth Israel Deaconess Medical Center, a Teaching Hospital of Harvard Medical School

WEST HAVEN, Conn.--(BUSINESS WIRE)--Oct. 31, 2005--NanoViricides, Inc. (Pink Sheets:NNVC - News), today announced that it has commenced preclinical studies for its anti-viral drug FluCide-I(TM). The studies are being conducted at the Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School, under the direction of Dr. Krishna Menon. Dr. Menon, the Company's Chief Regulatory Officer, explained that nanoviricides are complex materials. "We have started working on the basic safety of the polymer under a maximum tolerated dose protocol in mice. In the second part we will study the ligands that target FluCide-I(TM) to H5N1 and common influenza viruses. Thereafter, we will study the efficacy of FluCide-I(TM) itself against H5N1 and common influenza."


Dr. Anil Diwan, President, explained that, "if successful, the relevance of nanoviricides can be compared to the discovery of Penicillin, the very first bactericide. Prior to antibiotics, bacterial infections were treated with patient isolation, chicken soup and Vitamin C. Current anti-viral medicines can at best only partially inhibit the virus from multiplying in the human body. Although we cannot make claims of certainty yet, after we get good results from these studies we will be able to say that we have developed a true virus killer."

The Company is encouraged by the recent statements from high level international officials and health ministers of different countries concerning the urgency of developing effective vaccines and treatments and believes that a rapid regulatory approval of FluCide-I(TM), is possible should these studies be successful.

http://www.nanoviricides.com

5 comments:

Anonymous said...

H Allan,
Thanks so much for your continued sharing of your experience in the markets. You are a treasure in a sea of insanity. I am working on my own game plan and am wondering if you had the chart with the 3 indicators when you started in July 2003, or did all 3 come by the fall of 2004?
Blessings,

Frank D.

Allan said...

Frank, thanks for the kind words, but, WHAT CHART, WHAT INDICATORS are you talking about? Charts and indicators just get in the way for me anyway.

A

Gordo said...

Hi Allan, thanks again for your comments and glad to hear you bought some nnvc more at .55, i am very confident on this company and i don't talk only about share evolution but about what their drugs can bring to us people.
About the share: do you see it breaking the ,60 and going to ,80 anticipating succesful clinical tests before meeting in Vietnam or, as I see, going back to ,50-0,45 until those succesful results become really true?
Thank you for your coments and sorry for my english.

Gordo said...

I mean PRE-clinical tests, sorry.

gordo said...

I said nothing, 0,70! let's hope closes above 0,60. Congratulations!